Drug Profile
Research programme: GAI 122 nanoemulsion - Gaia BioPharma
Alternative Names: GAI-122Latest Information Update: 03 Jul 2013
Price :
$50
*
At a glance
- Originator AlphaRx
- Developer AlphaRx; Gaia BioPharma
- Class
- Mechanism of Action Antioxidants; Transferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Delirium; Hepatitis; Stroke
- Discontinued Cardiovascular disorders
Most Recent Events
- 01 Jul 2013 No development reported - Preclinical for Delirium in USA (Parenteral)
- 01 Jul 2013 No development reported - Preclinical for Hepatitis in China (Parenteral)
- 01 Jul 2013 No development reported - Preclinical for Stroke in China (Parenteral)